BioCentury | Sep 25, 2020
Finance

With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

...diseases and neuroscience. Pureos’ recent investments include Dutch bispecifics company Lava Therapeutics B.V. and oligonucleotide play Vico Therapeutics B.V....
BioCentury | Jul 29, 2020
Finance

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

...of a program founder and Chairman Luc Dochez knows well from his time at Prosensa. Vico Therapeutics B.V....
...Prosensa; he represented AGF Private Equity, which is now Idinvest Partners. Paul Bonanos, Associate Editor LSP Kurma Partners S.A. Vico Therapeutics B.V....
BioCentury | Apr 29, 2020
Finance

Kurma closes new fund at €160M, triple size of previous fund

...for endocrine play Alize Pharma and the €20 million series A round of neurology company Vico Therapeutics B.V....
Items per page:
1 - 3 of 3
BioCentury | Sep 25, 2020
Finance

With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

...diseases and neuroscience. Pureos’ recent investments include Dutch bispecifics company Lava Therapeutics B.V. and oligonucleotide play Vico Therapeutics B.V....
BioCentury | Jul 29, 2020
Finance

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

...of a program founder and Chairman Luc Dochez knows well from his time at Prosensa. Vico Therapeutics B.V....
...Prosensa; he represented AGF Private Equity, which is now Idinvest Partners. Paul Bonanos, Associate Editor LSP Kurma Partners S.A. Vico Therapeutics B.V....
BioCentury | Apr 29, 2020
Finance

Kurma closes new fund at €160M, triple size of previous fund

...for endocrine play Alize Pharma and the €20 million series A round of neurology company Vico Therapeutics B.V....
Items per page:
1 - 3 of 3